{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:44:48Z","timestamp":1773434688177,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Pharmacological inhibition of the renin-angiotensin-aldosterone-system (RAASi) is the cornerstone of hypertension treatment, renoprotection and secondary prevention of cardiovascular disease in patients with type 2 diabetes. Although there is a dose-dependent effect of RAASi with optimum protection when using maximal dose, little is known on actual use of maximal dosage RAASi in clinical practice. Here we investigate prevalence of maximal dosage RAASi, and contraindications for, optimizing RAASi dosage, in patients with complicated type 2 diabetes in a real-life clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis in 668 patients included in the DIAbetes and LifEstyle Cohort Twente (DIALECT). We grouped patients according to no RAASi, submaximal RAASi and maximal RAASi use. All potassium and creatinine measurements between January 1st 2000 and date of inclusion in DIALECT were extracted from patients files. We identified determinants of maximal RAASi use vs. submaximal RAASi use with multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean age was 64\u2009\u00b1\u200910 years and 61% were men. In total, 460 patients (69%) used RAASi, and 30% used maximal RAASi. Maximal RAASi use was not statistically different between different indications for RAASi (i.e. hypertension, diabetic kidney disease, coronary heart disease and cerebrovascular disease;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Per patient, 2 [1-4]\u00a0measurements of potassium and 20 [13\u201331] measurements of creatinine were retrieved, retrospective follow-up time was \u2212\u20093.0 [-1.4 to -5.7] years. Pre-baseline hyperkalemia\u2009&gt;\u20095.0 mmol\/l and acute kidney injury were found in 151 (23%) patients and 119 patients (18%), respectively. Determinants of maximal RAASi were prior acute kidney injury (OR 0.51 (0.30\u20130.87)), increased albuminuria (OR 1.89 (1.17\u20133.08)) and total number of used antihypertensives (OR 1.66 (1.33\u20132.06)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maximal dose RAASi is used in almost one third of complicated type 2 diabetes patients in a real-life setting. The prevalence of contraindications is considerable, but relative in nature, suggesting that it is worthwhile to explore strategies aimed at maximizing RAASi while circumventing the alleged contraindications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03205-2","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T06:02:33Z","timestamp":1692165753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes \u2013 contraindications and opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"C. M.","family":"Gant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Binnenmars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Navis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Haverkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. D.","family":"Laverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"3205_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"3205_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825\u201330.","journal-title":"Ann Intern Med"},{"key":"3205_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"3205_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"3205_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"3205_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Br\u00f6chner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"3205_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(03)12803-6","volume":"361","author":"L Vogt","year":"2003","unstructured":"Vogt L, Laverman GD, de Zeeuw D, Navis G. The COOPERATE trial. Lancet. 2003;361:1055\u20136.","journal-title":"Lancet"},{"key":"3205_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941\u201351.","journal-title":"N Engl J Med"},{"key":"3205_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11936-011-0126-9","volume":"13","author":"HA Tran","year":"2011","unstructured":"Tran HA, Schwartzbard A, Weintraub HS. Role of RAAS Inhibition in the Prevention of Cardiovascular Disease. Curr Treat Options Cardiovasc Med. 2011;13:279\u201388.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"3205_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1185\/03007995.2015.1053047","volume":"31","author":"S Taddei","year":"2015","unstructured":"Taddei S. RAS inhibitors\u2019 dose-dependent efficacy: myth or reality? Curr Med Res Opin. 2015;31:1245\u201356.","journal-title":"Curr Med Res Opin"},{"key":"3205_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1464-5491.2011.03341.x","volume":"28","author":"CL Blacklock","year":"2011","unstructured":"Blacklock CL, Hirst JA, Taylor KS, et al. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in type 2 diabetes: a meta-analysis. Diabet Med. 2011;28:1182\u20137.","journal-title":"Diabet Med"},{"key":"3205_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11586670-000000000-00000","volume":"11","author":"S Taddei","year":"2011","unstructured":"Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs. 2011;11:13\u201320.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3205_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1053\/ajkd.2001.29262","volume":"38","author":"GD Laverman","year":"2001","unstructured":"Laverman GD, Henning RH, de Jong PE, et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001;38:1381\u20134.","journal-title":"Am J Kidney Dis"},{"key":"3205_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00125-009-1328-5","volume":"52","author":"GD Laverman","year":"2009","unstructured":"Laverman GD, Bakker SJL, Navis GJ. Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue? Diabetologia. 2009;52:1217\u20138.","journal-title":"Diabetologia"},{"key":"3205_CR15","first-page":"212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21:212.","journal-title":"Am J Manag Care"},{"issue":"7","key":"3205_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/nu9070709","volume":"9","author":"CM Gant","year":"2017","unstructured":"Gant CM, Binnenmars SH, Berg E, et al. Integrated assessment of pharmacological and nutritional cardiovascular risk management: blood pressure control in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Nutrients. 2017;9(7):709. https:\/\/doi.org\/10.3390\/nu9070709.","journal-title":"Nutrients"},{"key":"3205_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","volume":"178","author":"S Brar","year":"2018","unstructured":"Brar S, Ye F, James MT, et al. Association of Angiotensin-Converting enzyme inhibitor or angiotensin receptor blocker Use with Outcomes after Acute kidney Injury. JAMA Intern Med. 2018;178:1681\u201390.","journal-title":"JAMA Intern Med"},{"key":"3205_CR18","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u201315.","journal-title":"Hypertension"},{"key":"3205_CR19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"3205_CR20","doi-asserted-by":"publisher","first-page":"d4366","DOI":"10.1136\/bmj.d4366","volume":"343","author":"MCJ Slagman","year":"2011","unstructured":"Slagman MCJ, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.","journal-title":"BMJ"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03205-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03205-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03205-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:11:52Z","timestamp":1700295112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03205-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3205"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03205-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1174424\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by local institutional review boards (METC-Twente, NL57219.044.16; METC-Groningen, 1009.68020), is registered in the Netherlands Trial Register (NTR trial code 5855) and is performed according to the guidelines of good clinical practice and the declaration of Helsinki as revised in 2008. All participants signed an informed consent form before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}